b) being attached via a spacer (= B) to a base matrix (= M') insoluble in the aqueous media used, the matrix with the attached ligand being represented by M-B-X

where M is the matrix, B is the spacer and X the affinity ligand, with the provision that M may contain further groups X linked via a spacer, characterized in that said ligand X has been selected among serum albuminbinding structures complying with the formulae

$$R_2$$
 R_3
 R_4

in which

- a) the free valence bind to the spacer B;
- b) R₁₋₄ are selected from hydrogen, electron-withdrawing groups, such as halogens and lower alkyl groups (C_{1-10}) that possibly are substituted with electron withdrawing groups, such as halogens;
- c) Z and Y are selected among oxygen, sulphur or nitrogen, with the provision that the nitrogen may carry a positive charge.

Please amend claim 3 as follows:

(once amended) The method according to [anyone of claims 1-2] claim 1, characterized in that at least one of R1-4 exhibit an electron withdrawing group, preferably selected among halogens such as fluorine.

Please amend claim 4 as follows

4. (once amended) The method according to [anyone of claims 1-3] claim 1, **characterized** in that the spacer [have] has a sulphur atom next to X.

3.

Please amend claim 5 as follows:

5. (once amended) The method according to [any one of claims 1-4]claim 1, characterized in that Z and Y are nitrogens, one of which binding to a hydrogen and the ligand structure being charged depending of pH.

Please amend claim 6 as follows:

6. (once amended) The method of [anyone of claims 1-5]claim 1, characterized in that said mixture derives from a host in which said serum albumin is human serum albumin.

Please amend claim 7 as follows:

7. (once amended) The method of [anyone of claims1-6] claim 1, characterized in ----that said-ligand is attached covalently to said matrix.

Please amend claim 8 as follows:

8. (once amended) The method of [anyone of claims 1-7]claim1, characterized in that after the adsorption step said serum albumin is eluted from said affinity adsorbent and if necessary further processed.

Remarks

Claims 1-10 are pending in the instant application. Applicants have amended claims 1, 3, 4, 5, 6, 7, and 8 to more fully conform with U.S. practice and to delete multiple dependencies. A version of the claims marked up to show the amendments, as well as a clean version of the claims encompassing the amendments, is attached hereto.